Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences
Open accessThe DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index; 26 of the 102 sources its claims cite were checked for support.
Abstract
The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease.
Overview
CoChat Summary
TL;DR
This narrative review argues that insulin resistance is the core mechanism linking sarcopenic obesity to cardiometabolic disease through fat accumulation, inflammation, mitochondrial dysfunction, and impaired insulin signaling in skeletal muscle. It further discusses how myokine–adipokine crosstalk and hormonal changes aggravate sarcopenic obesity and its cardiovascular, metabolic, and hepatic consequences.
Key findings
- Sarcopenic obesity is associated with a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone, and it combines muscle loss with fat accumulation, including intramyocellular lipid, intermyocellular adipose tissue, and peri-muscular adipose tissue.
- In skeletal muscle, lipid intermediates such as DAG and ceramides activate PKC, JNK, IKK/NF-kB, and related pathways, causing serine/threonine phosphorylation of insulin receptor/IRS-1, impaired PI3K/Akt signaling, and reduced GLUT4 translocation; this impairs glucose uptake and promotes muscle atrophy.
- Inflammation is central: adipose tissue macrophage staining is approximately 10% in lean subjects but up to 50% in obese subjects, and proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 contribute to insulin resistance, muscle atrophy, and cardiometabolic disease.
- Sarcopenic obesity and insulin resistance are linked clinically to atherosclerosis/cardiovascular disease, chronic heart failure, type 2 diabetes mellitus, metabolic syndrome, and NAFLD; skeletal muscle accounts for approximately 80–90% of postprandial glucose uptake, making muscle insulin resistance crucial in diabetes pathogenesis.
Methods
- Design: narrative review of molecular and clinical literature on sarcopenic obesity, insulin resistance, and cardiometabolic disease.
- Data/sample: no primary cohort or experimental sample; the paper synthesizes prior human, animal, and in vitro studies and cites clinical examples, including studies on carotid intima-media thickness, myocardial infarction, chronic heart failure, type 2 diabetes, metabolic syndrome, and NAFLD.
- Main analysis: thematic synthesis of mechanisms, including fat accumulation, inflammation, sex/growth hormone deficiency, skeletal muscle insulin signaling pathways, myocyte–adipocyte crosstalk, and pathophysiological links to cardiometabolic diseases.
Limitations
- The paper states that the definition of sarcopenic obesity has not been universally established and that different diagnostic criteria have different clinical implications.
- The paper repeatedly notes conflicting or insufficient evidence, including controversy over irisin and exercise, adiponectin’s clinical role, JAK/STAT signaling in muscle insulin resistance, and whether obesity itself is more predictive than sarcopenia for metabolic syndrome in some studies.
- Evident from the text: as a narrative review without a stated systematic search strategy, risk-of-bias assessment, or meta-analysis, it cannot quantify effect sizes or resolve heterogeneity across the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Valid · 4 Not valid · 62 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A British regional health study reported that older subjects with sarcopenic obesity had the highest cardiovascular mortality [113].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 4. Pathophysiological Link among Cardiometabolic Disease, Sarcopenic Obesity, and Insulin Resistance > 4.1. Atherosclerosis and Cardiovascular Disease
What the sources say
- Disputedcites [113] Atkins J.L. Whincup P.H. Morris R.W. Lennon L.T. Papacosta O. Wannamethee S.G. Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men J. Am. Geriatr. Soc. 2014 62 253 260 10.1111/jgs.12652 24428349 PMC4234002 sourceExperimental — accuracy not yet measured
Our copy (Abstract Conclusion; Discussion, and Discussion > Strengths and Limitations) states the opposite for cardiovascular mortality: 'Sarcopenic obese men had the highest risk of all-cause mortality but not CVD mortality,' and the Abstract Results add that CVD mortality risk was significantly greater in sarcopenic and obese but NOT sarcopenic obese men. The only point at which the sarcopenic obese group topped CVD mortality was the age-adjusted model, which lost significance after adjustment for lifestyle variables (Results). The highest-risk finding the paper reports for sarcopenic obesity is all-cause mortality (HR = 1.72, 95% CI = 1.35–2.18), so the claim substitutes CVD mortality for all-cause mortality; it also generalises 'older men' (British Regional Heart Study, aged 60–79) to 'older subjects'. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This complex disorder results in a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone [14].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.1. Definition
What the sources say
- Partly supportedcites [14] Rolland Y. Lauwers-Cances V. Cristini C. Abellan van Kan G. Janssen I. Morley J.E. Vellas B. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l’OSteoporose) Study Am. J. Clin. Nutr. 2009 89 1895 1900 10.3945/ajcn.2008.26950 19369381 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report roughly 2–3 times higher odds of difficulty with several physical tasks for sarcopenic-obese women than for purely sarcopenic women. Compared with purely obese women, however, the difference was statistically significant only for going down stairs. The study measured self-reported functional difficulties in a cross-sectional sample, not a general 2–3-fold higher risk of developing disability than either group. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intermyocellular adipose tissue (IMAT) and IMCL secrete myostatin, CCL2, TNF-α, IL-1β, and IL-6, thus inducing IR and lipotoxicity, which is discussed in the next section [30].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [30] Rivas D.A. McDonald D.J. Rice N.P. Haran P.H. Dolnikowski G.G. Fielding R.A. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016 310 R561 R569 10.1152/ajpregu.00198.2015 26764052 PMC4867383 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links lipid accumulation in obesity to inflammation and secretion of TNF-α, IL-1β, and IL-6. It does not say that IMAT and IMCL themselves secrete those cytokines or myostatin and CCL2, nor does it establish that such secretion induces insulin resistance and lipotoxicity. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The amount of PMAT is correlated with the severity of muscle atrophy [31].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Supportedcites [31] Zhu S. Tian Z. Torigoe D. Zhao J. Xie P. Sugizaki T. Sato M. Horiguchi H. Terada K. Kadomatsu T. Aging-and obesity-related peri-muscular adipose tissue accelerates muscle atrophy PLoS ONE 2019 14 e0221366 10.1371/journal.pone.0221366 31442231 PMC6707561 source
The Results section, “PMAT accumulation increases with muscle atrophy in aged mice,” reports that mice with at least 5% PMAT had lower muscle mass and muscle-fiber cross-sectional area than mice with less than 5% PMAT. The authors describe the degree of PMAT deposition as associated with progression of muscle atrophy in aged mice. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low GH levels reduce IGF1 action by sequentially downregulating the PI3K-AKT/PKB-mTOR pathway, which induces protein synthesis in muscles [49].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [49] Egerman M.A. Glass D.J. Signaling pathways controlling skeletal muscle mass Crit. Rev. Biochem. Mol. Biol. 2014 49 59 68 10.3109/10409238.2013.857291 24237131 PMC3913083 sourceExperimental — accuracy not yet measured
The section on IGF1/PI3K/Akt hypertrophy signaling (page not provided) describes IGF1 activating PI3K/Akt and mTORC1 signaling in skeletal muscle; its Figure 1 caption links that signaling to protein synthesis. The passages do not say that low growth hormone (GH) levels reduce IGF1 action or downregulate this pathway. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 9 with their cited sources checked
Create a free account to see all 95 claims and to verify the 76 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various myokines released from active muscles act as signalling mediators between skeletal muscle and other vital organs, such as the liver, fat, and brain.[ 5 ]”
From Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondly, metabolic disorders including cardiometabolic syndrome (CMS), diabetes, cardiovascular disease (CVD), and cancer are common comorbidities of SO (54, 55).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, in fl ammation, and insulin resistance, all which negatively affect muscle mass [6].”
From Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement (2022) · cites this paper as [6]
In the citing paper
“Aging-associated increases in visceral fat and reduced muscle mass are correlated with multiple adverse cardiometabolic effects and contribute to poor health outcomes (119).”
From Health Consequences of Sarcopenic Obesity: A Narrative Review (2020) · cites this paper as [119]
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, inflammation and insulin resistance, all of which negatively affect muscle mass [6].”
From Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 3×
“EWGSOP2 [2] Use the SARC-F questionnaire to find subjects with sarcopenia Decreased muscle mass and Decreased muscle strength or performance NA”
BackgroundMethodObesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“In adipose tissue from lean subjects, approximately 10% of cells stained positive for macrophages, but in obese subjects, this number increased to up to 50% [38].”
BackgroundInflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · cited 1×
“Atherogenesis is a complicated process that includes oxidative stress, inflammation, endothelial dysfunction, vascular proliferation, and thrombosis [104].”
BackgroundIncreased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 2×
“It causes the dysregulation of adipocytokines, such as adiponectin, PAI-1, IL-6, and MCP-1, leading to metabolic syndrome [134].”
BackgroundA PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810 · cited 1×
“Irisin is a PPARγ-coactivator-1α (PGCα)-dependent myokine that stimulates browning in subcutaneous adipose tissues and induces increased energy expenditure, which improves obesity and IR through the MAPK and ERK pathways [92,93].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238 · cited 1×
“Thus, it facilitates insulin sensitivity by increasing glucose uptake in skeletal muscle and by stimulating fatty acid oxidation through activation of the 5′-AMP-activated protein kinase (AMPK) signaling pathway [100].”
BackgroundSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 3×
“Sarcopenia results in a decreased metabolic rate, low physical activity, and myokine deficiency, which collectively leads to the proinflammatory effect, and exacerbates obesity.”
BackgroundInfluentialSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“Moreover, obesity accompanies the accumulation of lipids in the liver, thus aggravating insulin resistance in hepatocytes [141].”
BackgroundA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“Inflammation due to sarcopenic obesity results in reduced NO, cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) activity in cardiomyocytes, leading to LV hypertrophy and stiffness [120].”
Background
Research works printed but not linked: 1
- White A.T. Schenk S. Knockout of STAT3 in skeletal muscle does not enhance insulin action Diabetologia 2013 56 S250
Cited by
Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Obesity Facts · doi:10.1159/000521241 · Cited by 1,019
The crucial role and mechanism of insulin resistance in metabolic disease
Zhao, X., An, X., Yang, C., Sun, W., Ji, H., & Lian, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149239 · Cited by 557
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“Hence, IR and inflammation form a vicious circle, each condition promoting the other and accelerating the development of NAFLD and other metabolic disorders in the presence of lipotoxicity [107].”
BackgroundPathogenesis of sarcopenia and the relationship with fat mass: descriptive review
Li, C., Yu, K., Shyh‐Chang, N., Jiang, Z., Liu, T., Ma, S., Luo, L., Guang, L., Liang, K., Ma, W., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12901 · Cited by 626
“obesity, is the concurrence of muscle loss and excessive body fat accrual.([59]) The definition of SO has not been universally”
BackgroundDefinition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-depen-dent metabolic derangements, such as oxidative stress, inflammation and insulin resistance, all of which negatively affect muscle mass [6].”
Sarcopenia during COVID-19 lockdown restrictions: long-term health effects of short-term muscle loss
Kirwan, R., McCullough, D., Butler, T., Perez de Heredia, F., Davies, I. G., & Stewart, C. (2020) · GeroScience · doi:10.1007/s11357-020-00272-3 · Cited by 324
Health Consequences of Sarcopenic Obesity: A Narrative Review
Roh, E., & Choi, K. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00332 · Cited by 304
“Aging-associated increases in visceral fat and reduced muscle mass are correlated with multiple adverse cardiometabolic effects and contribute to poor health outcomes (119).”
BackgroundSelf-citationSarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
“This state is characterized by insulin resistance (IR), which induces vasodilation lesion and endothelial dysfunction, thus fueling the advancement of atherosclerosis (54).”
BackgroundMediterranean diet nutrients to turn the tide against insulin resistance and related diseases
Mirabelli, M., Chiefari, E., Arcidiacono, B., Corigliano, D. M., Brunetti, F. S., Maggisano, V., Russo, D., Foti, D. P., & Brunetti, A. (2020) · Nutrients · doi:10.3390/nu12041066 · Cited by 272
“IR affects approximately 25%–35% of Westernized populations [2] and is consistently associated with obesity [3] and obesity-related complications, such as type 2 diabetes (T2D) mellitus [4], cardiovascular disease (CVD) [5,6], certain types of cancer [7], infertility [8], non-alcoholic fatty liver disease (NAFLD) [9,1…”
BackgroundBilski, J., Pierzchalski, P., Szczepanik, M., Bonior, J., & Zoladz, J. (2022) · Cells · doi:10.3390/cells11010160 · Cited by 251
Papadopoulou, S. K., Papadimitriou, K., Voulgaridou, G., Georgaki, E., Tsotidou, E., Zantidou, O., & Papandreou, D. (2021) · Nutrients · doi:10.3390/nu13124499 · Cited by 231
“It has been shown that the loss of muscle mass that accompanies sarcopenia leads to increased insulin resistance, which promotes the development of metabolic syndrome and obesity [8].”
BackgroundTamura, Y., Omura, T., Toyoshima, K., & Araki, A. (2020) · Nutrients · doi:10.3390/nu12113367 · Cited by 224
“The various diagnostic criteria that have been proposed and used for sarcopenic obesity hinder the effective comparison and meta-analysis of various studies conducted on sarcopenic obesity [96].”
BackgroundInfluentialDiabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
Bansal, S. K., & Bansal, M. B. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17930 · Cited by 178
“71 As muscle insulin resistance perpetuates with decreased glucose uptake and glycogen synthesis, increased FAA beta oxidation increases ROS causing myocyte toxicity and development of sarcopenia.”
BackgroundProtein Intake and Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis
Coelho-Junior, H., Calvani, R., Azzolino, D., Picca, A., Tosato, M., Landi, F., Cesari, M., & Marzetti, E. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148718 · Cited by 149
“Such dietary regimes are associated with an increased risk of obesity which, in turn, promotes the development of insulin resistance, oxidative stress, low-grade systemic inflammation, and hormonal changes [53].”
BackgroundExercise therapy for people with sarcopenic obesity: myokines and adipokines as effective actors
Alizadeh Pahlavani, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.811751 · Cited by 145
Sarcopenic Obesity: An Emerging Public Health Problem
Ji, T., Li, Y., & Ma, L. (2022) · Aging and disease · doi:10.14336/ad.2021.1006 · Cited by 124
“Numerous molecules (TNF-α, IL-6, IL-1, adiponectin, leptin, muscle somatostatin, sex hormones (testosterone and estrogen), growth hormone, insulin and glucocorticoid, and irisin) have been implicated in the pathogenesis of SO [50].”
BackgroundInfluentialGortan Cappellari, G., Guillet, C., Poggiogalle, E., Ballesteros Pomar, M. D., Batsis, J. A., Boirie, Y., Breton, I., Frara, S., Genton, L., Gepner, Y., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.02.018 · Cited by 113
González, A., Huerta-Salgado, C., Orozco-Aguilar, J., Aguirre, F. S., Tacchi, F., Simón, F., & Cabello‐Verrugio, C. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1617805 · Cited by 129
“Patients with NAFLD can develop IR and obesity, together with sarcopenia and muscle fibrosis, which can have to OS as a common cause [77].”
BackgroundJiang, M., Ren, X., Han, L., & Zheng, X. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.02.002 · Cited by 120
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R., Guastamacchia, E., De Pergola, G., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 101
“Instead, it is followed by an improvement The mechanisms involved in sarcopenic obesity are similar to those described for sarcopenia. in skeletal muscle [32].”
BackgroundChristensen, S., Robinson, K., Thomas, S., & Williams, D. R. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100121 · Cited by 108
“Outside of people with T2DM, sarcopenia in older adults is associated with poor outcomes including poor physical function, poor quality of life, and reduced survival, therefore, adequate protein is emphasized to support muscle health [6,10,39,41].”
BackgroundObesity phenotypes and cardiovascular risk: From pathophysiology to clinical management
Preda, A., Carbone, F., Tirandi, A., Montecucco, F., & Liberale, L. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09813-5 · Cited by 142
“inflammation and IR) [79] and indirectly through increased prevalence of obesity-related chronic diseases with a negative impact on muscle metabolism (i.”
BackgroundLópez-Pedrosa, J. M., Camprubí-Robles, M., Rolo, G. G., Lopez-Gonzalez, A., García‐Almeida, J. M., Sanz‐París, A., & Rueda, R. (2024) · Nutrients · doi:10.3390/nu16010172 · Cited by 117
Implication of Obesity and Gut Microbiome Dysbiosis in the Etiology of Colorectal Cancer
Singh, S., Sharma, P., Sarma, D. K., Kumawat, M., Tiwari, R. R., Verma, V., Nagpal, R., & Kumar, M. (2023) · Cancers · doi:10.3390/cancers15061913 · Cited by 90
“Sarcopenic obesity (SO) is caused by a number of endocrine-hormonal, metabolic, and lifestyle factors that, in turn, influence pathophysiological factors that may aid in the development of cancer [15,16].”
BackgroundSpotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions
de Lima, E. P., Tanaka, M., Lamas, C. B., Quesada, K., Detregiachi, C. R. P., Araújo, A. C., Guiguer, E. L., Catharin, V. M. C. S., de Castro, M. V. M., Junior, E. B., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092096 · Cited by 73
Vitamin D in Osteosarcopenic Obesity
di Filippo, L., LORENZO, R. D., Giustina, A., Rovere, P. Q., & Conte, C. (2022) · Nutrients · doi:10.3390/nu14091816 · Cited by 79
“Although the association between sarcopenic obesity and insulin resistance is widely recognized [35], few studies so far have assessed the relationship between osteosarcopenic obesity and insulin resistance.”
BackgroundImpact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
Iwaki, M., Kobayashi, T., Nogami, A., Saito, S., Nakajima, A., & Yoneda, M. (2023) · Nutrients · doi:10.3390/nu15040891 · Cited by 69
“These cytokines promote protein decay in skeletal muscle [2,51,54].”
BackgroundEvans, K., Abdelhafiz, D., & Abdelhafiz, A. H. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1942934 · Cited by 61
Silveira, É. A., Filho, R. R. D. S., Spexoto, M. C. B., Haghighatdoost, F., Sarrafzadegan, N., & de Oliveira, C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094339 · Cited by 63
“Angiotensin II and aldosterone, in turn, act on their endothelial receptors and also on the heart muscle, reducing the production of nitric oxide and activating myocardial tissue remodeling pathways [17].”
BackgroundInfluentialAzevedo, V. Z., Silaghi, C. A., Maurel, T., Silaghi, H., Ratziu, V., & Pais, R. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.774030 · Cited by 67
“Irisin improves glucose metabolism, increases adipocyte energy expenditure, modulates the expression of enzymes that inhibit lipid accumulation and reduces weight and has a positive effect on hepatic steatosis (24, 119, 120).”
BackgroundInfluentialWannamethee, S. G., & Atkins, J. L. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01522-2 · Cited by 49
“…of pathological mechanisms underlying age-related muscle loss have been identified including neuronal and hormonal changes, being underweight, poor nutrition, physical inactivity, insulin resistance and inflammation [13–20]; thus, sharing many pathological mechanisms with atherosclerosis [14, 20].”
BackgroundHwang, J., & Park, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20021140 · Cited by 52
Minniti, G., Pescinini-Salzedas, L. M., Minniti, G. A. D. S., Laurindo, L. F., Barbalho, S. M., Sinatora, R. V., Sloan, L. A., Haber, R. S. D. A., Araújo, A. C., Quesada, K. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113452 · Cited by 56
Gengxin, Y., Xuehan, M., Xinyu, W., Yali, Y., Yiran, X., Zheng, L., Qiu, Y., Li, G., & Chen, L. (2025) · Age and Ageing · doi:10.1093/ageing/afae286 · Cited by 56
Ryu, J. Y., Choi, H. M., Yang, H.-I., & Kim, K. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186887 · Cited by 55
“It is recognized that SOB is clinically associated with other iseases [14,94,95].”
BackgroundTowards an adiposity-related disease framework for the diagnosis and management of obesities
Perdomo, C. M., Avilés-Olmos, I., Dicker, D., & Frühbeck, G. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09797-2 · Cited by 56
“Obesity can independently lead to loss of muscle mass and function, due to oxidative stress, inflammation and IR [54, 55].”
BackgroundGao, Y.-M., Chen, W., Deng, Z., Shang, Z., & Wang, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150980 · Cited by 44
“Insulin resistance (IR), characterized as the inability of cells to react to insulin action, is a prominent feature of T2DM and is linked to a wide range of clinical conditions, including cognitive impairment (9), non-alcoholic fatty liver disease (10), cardiovascular disease (CVD) (11), and CKD (12).”
BackgroundUpregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice
Yao, Z., Gong, Y., Chen, W., Shao, S., Song, Y., Guo, H., Li, Q., Liu, S., Wang, X., Zhang, Z., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00896-7 · Cited by 48
“…of the [ 11 C]acetate uptake experiment, which is used to assess the levels of DNL (upper), representative [ 11 C]acetate-PET imaging (lower left) and calculated liver [ 11 C]acetate uptake standard uptake value (SUV; lower right) were obtained. n = 3 biologically independent mice per group.”
BackgroundMethodInfluentialMatsushita, T., Nishioka, S., Taguchi, S., Yamanouchi, A., Nakashima, R., & Wakabayashi, H. (2020) · Healthcare · doi:10.3390/healthcare8030255 · Cited by 44
“SO may cause insulin resistance due to intramuscular fat accumulation [34,35].”
BackgroundSarcopenic Obesity: Involvement of Oxidative Stress and Beneficial Role of Antioxidant Flavonoids
Jung, U. J. (2023) · Antioxidants · doi:10.3390/antiox12051063 · Cited by 45
“Obesity can independently cause sarcopenia, because underlying factors contributing to obesity such as inflammation, insulin resistance, and oxidative stress can adversely affect sarcopenia [45].”
BackgroundThe Complexity of Oxidative Stress in Human Age-Related Diseases—A Review
Płóciniczak, A., Bukowska‐Olech, E., & Wysocka, E. (2025) · Metabolites · doi:10.3390/metabo15070479 · Cited by 51
“…socioeconomic policies, and financial sustainability, as aging is the primary risk factor for numerous chronic diseases, including cardiovascular disorders, type 2 diabetes mellitus, sarcopenia, neurodegenerative disorders such as Alzheimer’s disease, cancers, and frailty syndrome [4–6].”
Corsello, A., Scatigno, L., Pascuzzi, M. C., Calcaterra, V., Dilillo, D., Vizzuso, S., Pelizzo, G., Zoia, E., Mandelli, A., Govoni, A., et al. (2021) · Nutrients · doi:10.3390/nu13072400 · Cited by 46
“Among females, in milder SMA patients, thelarche and menarche appeared at a normal age, and regular menstrual cycles are usually reported [93].”
BackgroundResultInfluentialDeng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lü, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03129-6 · Cited by 42
“However, what is certain is that insulin resistance and inflammation form a vicious spiral that promotes each other and accelerates the development of NAFLD and other metabolic disorders in the presence of lipotoxicity [88].”
BackgroundSarcopenic obesity is significantly associated with coronary artery calcification
Chung, G. E., Park, H. E., Lee, H., Kim, M. J., Choi, S.-Y., Yim, J. Y., & Yoon, J. W. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.651961 · Cited by 39
“Thus, obesitymay aggravate sarcopenia, and sarcopeniamay exacerbate obesity by decreased metabolic rate and myokine deficiency (37); this vicious cycle may exert synergistic detrimental effects on cardiovascular risk.”
BackgroundJang, Y. J. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2210.10014 · Cited by 49
Gortan Cappellari, G., Semolic, A., Zanetti, M., Vinci, P., Ius, M., Guarnieri, G., Busetto, L., Donini, L. M., & Barazzoni, R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155595 · Cited by 36
Defining and diagnosing sarcopenia: Is the glass now half full?
Barazzoni, R., Cederholm, T., Zanetti, M., & Cappellari, G. G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155558 · Cited by 38
Zhang, J., Na, X., Li, Z., Ji, J. S., Li, G., Hai-bing, Y., Yang, Y., Tan, Y., Zhang, J., Xi, M., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03357-4 · Cited by 43
“Since progression of obesity and sarcopenic obesity differs between women and men, all analyses were stratified by sex [32, 33].”
BackgroundBellafronte, N. T., Ono, A. D. Q. M., & Chiarello, P. G. (2021) · Medical Principles and Practice · doi:10.1159/000517597 · Cited by 40
Zou, Y., Ye, H., Xu, Z., Yang, Q., Zhu, J., Li, T., Cheng, Y., Zhu, Y., Zhang, J., Bo, Y., et al. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae284 · Cited by 35
Sun, L., Fu, J., Mu, Z., Duan, X., Chan, P., & Xiu, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1094075 · Cited by 37
“In addition, excess adiposity may reduce insulin action, which has pro-catabolic effects on muscle (8).”
BackgroundAssociation between sarcopenia and prediabetes among non-elderly US adults
Xu, J., Han, X., Chen, Q., Cai, M., Tian, J., Yan, Z., Guo, Q., Xu, J., & Lü, H. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02038-y · Cited by 35
“All the above-mentioned risk results could not be separated from an important pathologic link—insulin resistance (IR) [31].”
BackgroundEsposito, M., & Mandalà, M. (2025) · Biomolecules · doi:10.3390/biom15020284 · Cited by 36
Is dynapenic abdominal obesity a risk factor for cardiovascular mortality? A competing risk analysis
Ramírez, P. C., de Oliveira, D. C., Máximo, R. D. O., de Souza, A. F., Luiz, M. M., Delinocente, M. L. B., Steptoe, A., de Oliveira, C. M., & Alexandre, T. D. S. (2023) · Age and Ageing · doi:10.1093/ageing/afac301 · Cited by 34
Lu, L., He, X., Song, Y., Zhuang, M., Wu, X., & Chen, N. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1034542 · Cited by 32
“CVD is also accompanied by the pro-inflammatory state and insulin resistance (Wu and Ballantyne, 2017), which may lead to a decrease in muscle mass and an increase in fat mass, and ultimately develop into SO (Hong and Choi, 2020).”
BackgroundAssociation between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
Song, W., Yoo, S. H., Jang, J., Baik, S. J., Lee, B. K., Lee, H. W., & Park, J. S. (2022) · Gut and Liver · doi:10.5009/gnl220041 · Cited by 33
“27,28 Both obesity and sarcopenia have been shown to be associated with the prevalence of NAFLD and liver fibrosis, and it has been proposed that it is more closely related to sarcopenic obesity, NAFLD, and liver fibrosis.”
Song, E., Hwang, S. Y., Park, M., Jang, A., Kim, K. J., Yu, J. H., Kim, N. H., Yoo, H. J., Seo, J. A., Kim, S. G., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155678 · Cited by 32
Self-citationCheah, K. J., & Cheah, L. J. (2023) · Nutrition Journal · doi:10.1186/s12937-023-00880-7 · Cited by 29
Sarcopenia: A dive into metabolism to promote a multimodal, preventive, and regenerative approach
Boccardi, V. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111941 · Cited by 34
Immuno-metabolic diseases and therapeutics: molecular mechanisms via inflammasome signaling
Han, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02368-9 · Cited by 36
“The loss of muscle mass and strength disrupts glucose metabolism and promotes insulin resistance, given the essential role of skeletal muscle in glucose uptake and utilization [149–151].”
Cai, X., Hu, J., Wang, M., Wen, W., Wang, J., Yang, W., Dang, Y., Luo, Q., Hong, J., & Li, N. (2023) · Aging · doi:10.18632/aging.204587 · Cited by 29
Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both
Wong, R., & Yuan, L. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i6.871 · Cited by 33
Kuo, Y.-K., Lin, Y., Lee, C., Chen, C., Tani, J., Huang, T., Chang, H. C., & Wu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083010 · Cited by 32
Jurdana, M., & Čemažar, M. (2024) · Radiology and Oncology · doi:10.2478/raon-2024-0011 · Cited by 30
“57-59 Inflammatory cytokines directly affect skeletal muscle and accelerate muscle proteins degradation and apoptosis and induces muscle tissue reduction and fat tissue accumulation.”
BackgroundRegeneration during Obesity: An Impaired Homeostasis
Ghanemi, A., Yoshioka, M., & St‐Amand, J. (2020) · Animals · doi:10.3390/ani10122344 · Cited by 28
“Importantly, the impact obesity has on skeletal muscle in terms of regeneration could worsen sarcopenic obesity and explain a part of its pathogenesis [33], including that shared with obesity and leading to commune outcomes such insulin resistance and cardiometabolic impacts [34], through reducing muscle regeneration…”
BackgroundKim, B., Kim, G.-M., Kim, E., Park, J., Isobe, T., Sakae, T., & Oh, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182412874 · Cited by 29
Prevalence of Risk of Sarcopenia in Polish Elderly Population—A Population Study
Milewska, M., Przekop, Z., Szostak-Węgierek, D. E., Chrzanowska, M., Raciborski, F., Traczyk, I., Sińska, B. I., & Samolinski, B. K. (2022) · Nutrients · doi:10.3390/nu14173466 · Cited by 29
“This could be due to sarcopenic obese individuals tending to accumulate fat in muscles, which could negatively affect skeletal muscle function through increased levels of proinflammatory cytokines [36].”
BackgroundCho, Y. K., Jung, H. N., Kim, E. H., Lee, M. J., Park, J., Lee, W. J., Kim, H., & Jung, C. H. (2023) · Obesity · doi:10.1002/oby.23733 · Cited by 28
“Obesity can induce the loss of skeletal muscle mass and impaired function because of its detrimental impact of adipose tissue-derived metabolic derangements, such as oxidative stress, inflammation, and insulin resistance [4].”
BackgroundGABA Prevents Age-Related Sarcopenic Obesity in Mice with High-Fat-Diet-Induced Obesity
Jin, H., Oh, H., & Lee, B.-Y. (2023) · Cells · doi:10.3390/cells12172146 · Cited by 27
“The synergistic effects of obesity and sarcopenia on glucose metabolism and insulin sensitivity cause dyslipidemia, glucose intolerance, and insulin resistance [16].”
BackgroundZhang, X., He, Z., Si, Q., Hu, X., Yang, L., Gu, X., Du, L.-J., Wang, L., Pan, L., Li, Y., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/2229139 · Cited by 28
“The current study suggested that SV indicated a higher risk for lean NAFLD in Chinese patients with T2DM than sarcopenia or visceral obesity alone.”
BackgroundInfluentialEffects of Fucoxanthin on the Inhibition of Dexamethasone-Induced Skeletal Muscle Loss in Mice
Yoshikawa, M., Hosokawa, M., Miyashita, K., Nishino, H., & Hashimoto, T. (2021) · Nutrients · doi:10.3390/nu13041079 · Cited by 25
“On the other hand, increasing body fat induces obesity, which causes secretion abnormalities of inflammatory cytokines, such as tumor necrosis factor alpha (TNFα) and insulin resistance [3].”
BackgroundWeight cycling based on altered immune microenvironment as a result of metaflammation
Li, W., & Chen, W. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00731-6 · Cited by 27
“Obesity and sarcopenia are associated with a decreased basal metabolic rate, increased oxidative stress, and metabolic issues [76].”
BackgroundChe, X., Shang, X., Weixu, Xing, M., Wei, H., Li, W., Li, Z., Teng, X., & Geng, L. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141204 · Cited by 27
Cho, Y., Park, H., Huh, B. W., Lee, Y., Seo, S., Seo, D. H., Ahn, S. H., Hong, S., & Kim, S. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0355 · Cited by 27
“The loss of muscle mass and muscle function, known as sar-copenia, is part of a physiologic aging process, and is usually exacerbated by low physical activity, malnutrition, and inflammatory conditions [6].”
Self-citationSarcopenic obesity — a current problem of modern geriatrics
Kurmaev, D. P., Bulgakova, S. V., & Treneva, E. V. (2023) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2022-228-235 · Cited by 32
Food insecurity as a risk factor of sarcopenic obesity in older adults
Fonseca-Pérez, D., Arteaga-Pazmiño, C., Maza-Moscoso, C. P., Flores-Madrid, S., & Álvarez-Córdova, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1040089 · Cited by 23
“Indeed, low levels of sex-specific hormones are an important factor related to SO (34).”
BackgroundInfluentialAssociation between dynapenic obesity and risk of cardiovascular disease: The Hisayama study
Setoyama, Y., Honda, T., Tajimi, T., Sakata, S., Oishi, E., Furuta, Y., Shibata, M., Hata, J., Kitazono, T., Nakashima, Y., et al. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13564 · Cited by 24
Sılay, K., & Öztorun, H. S. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06105-2 · Cited by 30
Sarcopenia‐related changes in serum GLP‐1 level affect myogenic differentiation
Huang, H., Wang, Y., Jiang, H., Yu, H. W., Chen, Y., Chiou, A., & Kuo, J. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13524 · Cited by 22
“23,24 Considering our fi ndings that consistent GLP-1 treatment contained the capability to affect glucose uptake of myotubes directly ( Figure 3A ), we conducted further investigations to ascertain whether consistent GLP-1 treatment could hinder insulin ’ s in fl uence on myotube glucose uptake.”
BackgroundMethodZhong, Y., Ren, J. F., Li, R., Xuan, Y., Yao, W., Yang, Q., Gan, Y., Yu, S., & Yuan, J. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.137701 · Cited by 22
Research Progress on the Effect and Mechanism of Exercise Intervention on Sarcopenia Obesity
Chen, J., Jia, S., Guo, C., Fan, Z., Yan, W., & Dong, K. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s473083 · Cited by 23
Nagano, F., Yoshimura, Y., Matsumoto, A., Bise, T., Kido, Y., Shimazu, S., & Shiraishi, A. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106429 · Cited by 21
Wijarnpreecha, K., Aby, E. S., Ahmed, A., & Kim, D. (2021) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3323 · Cited by 25
“A recent article discussed the association between sarcopenic obesity and insulin resistance and cardiometabolic diseases, including cardiovascular disease and type 2 diabetes, which were closely associated with NAFLD [17].”
BackgroundMetabolic-Associated Fatty Liver Disease and Sarcopenia
Bali, T., Chrysavgis, L., & Cholongitas, Ε. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.02.004 · Cited by 23
Ramírez, P. C., Máximo, R. D. O., de Oliveira, D. C., de Souza, A. F., Luiz, M. M., Delinocente, M. L. B., Steptoe, A., de Oliveira, C. M., & Alexandre, T. D. S. (2023) · The journal of nutrition health & aging · doi:10.1007/s12603-023-2039-1 · Cited by 21
Guan, Z., Minnetti, M., Heymsfield, S. B., Poggiogalle, E., Prado, C. M. M., Sim, M., Stephan, B. C. M., Wells, J. C. K., Donini, L. M., & Siervo, M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2024.100364 · Cited by 21
Moon, S., Choi, J. W., Park, J. H., Kim, D. S., Ahn, Y.-H., Kim, Y., Kong, S. H., & Oh, C. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13811 · Cited by 21
Sarcopenia, sarcopenic obesity, and arterial stiffness among older adults
Fantin, F., Giani, A., Manzato, G., Zampieri, A., Comellato, G., Urbani, S., Zoico, E., Mazzali, G., & Zamboni, M. M. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1272854 · Cited by 21
Damanti, S., Citterio, L., Zagato, L., Brioni, E., Magnaghi, C., Simonini, M., LORENZO, R. D., Ruggiero, M., Santoro, S., Senini, E., et al. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-05216-6 · Cited by 23
“On the one hand the increased fat tissue promotes oxidative stress, inflammation and the development of insulin resistance, which negatively act on the trophism and function of muscles [14].”
BackgroundAdvancements in sarcopenia diagnosis: from imaging techniques to non-radiation assessments
Lavalle, S., Scapaticci, R., Masiello, E., Messina, C., Aliprandi, A., Salerno, V. M., Russo, A., & Pegreffi, F. (2024) · Frontiers in Medical Technology · doi:10.3389/fmedt.2024.1467155 · Cited by 21
Kuchay, M. S., Choudhary, N. S., Gagneja, S., Mathew, A., Bano, T., Kaur, P., Bahadur, B., Singh, M. K., Gill, H. K., Wasir, J. S., et al. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15595 · Cited by 17
Wang, J., He, L., Yang, N. Y., Li, Z., Xu, L., Li, W., Ping, F., Zhang, H., & Li, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1054671 · Cited by 16
“In addition, IR and metabolic disorders are positively associated with all-cause mortality (5, 6).”
BackgroundYogesh, M., Patel, M., Makwana, H., & Kalariya, H. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00179-4 · Cited by 18
Lu, Z., Hu, Y., He, H., Chen, X., Ou, Q., Liu, Y., Xu, T., Tu, J., Li, A., Lin, B., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111783 · Cited by 21
Rosas‐Carrasco, Ó., Manrique-Espinoza, B. S., López-Alvarenga, J. C., Mena‐Montes, B., & Omaña‐Guzmán, I. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100368 · Cited by 18
“This inflammatory state is further exacerbated by fat infiltration into myocytes, negatively impacting both muscle and bone tissues [46 – 48].”
Ciesielka, J., Jakimów, K., Majewska, K., Mrowiec, S., & Jabłońska, B. (2024) · Nutrients · doi:10.3390/nu16203569 · Cited by 18
“It is worth noting that permanent inflammation during obesity may lead to insulin resistance and the downregulation of glucose transporter protein type-4, impairing glucose uptake and resulting in low skeletal muscle [25].”
BackgroundJones, A., & Silver, H. J. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.03.005 · Cited by 22
Lim, H., Son, K., & Lim, H. (2023) · Nutrients · doi:10.3390/nu15071574 · Cited by 16
“In addition, obesity causes fat accumulation in the muscles, which may promote insulin resistance, oxidative stress, and pro-inflammatory responses in overweight and obese populations, leading to sarcopenia [3].”
Background
Metadata
- Authors
- Hong, S.-H., & Choi, K. M.
- Affiliations
- Korea University (KR)
- Corresponding author
- Choi, Kyung Mook
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-13
- Volume
- 21
- Issue
- 2
- Pages
- 494
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7013734
- OpenAlex
- W2999215393
- Cited by
- 390
- References
- 153
- Citations by year
- 2026: 91 · 2025: 87 · 2024: 68 · 2023: 72 · 2022: 40 · 2021: 20 · 2020: 11
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Korea Christian University (Q1625561)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- sarcopenic obesity, insulin resistance, cardiometabolic disease, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, muscle atrophy, mitochondrial dysfunction, oxidative stress, myokines, adipokines, insulin signaling, aging
- MeSH terms
- Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Mitochondria, Liver, Mitochondria, Muscle, Obesity, Sarcopenia, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.